CN100384430C - 含有葡萄糖重吸收抑制剂和维生素a类-x受体调节剂的联合治疗 - Google Patents
含有葡萄糖重吸收抑制剂和维生素a类-x受体调节剂的联合治疗 Download PDFInfo
- Publication number
- CN100384430C CN100384430C CNB02810482XA CN02810482A CN100384430C CN 100384430 C CN100384430 C CN 100384430C CN B02810482X A CNB02810482X A CN B02810482XA CN 02810482 A CN02810482 A CN 02810482A CN 100384430 C CN100384430 C CN 100384430C
- Authority
- CN
- China
- Prior art keywords
- glucose reabsorption
- glucose
- reabsorption inhibitor
- purposes
- retinoid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Liquid Crystal (AREA)
- Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
- Laminated Bodies (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28147901P | 2001-04-04 | 2001-04-04 | |
| US60/281,479 | 2001-04-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1511038A CN1511038A (zh) | 2004-07-07 |
| CN100384430C true CN100384430C (zh) | 2008-04-30 |
Family
ID=23077475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB02810482XA Expired - Lifetime CN100384430C (zh) | 2001-04-04 | 2002-04-03 | 含有葡萄糖重吸收抑制剂和维生素a类-x受体调节剂的联合治疗 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US6838442B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1392326B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4590158B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN100384430C (cg-RX-API-DMAC7.html) |
| AT (1) | ATE442148T1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2443325C (cg-RX-API-DMAC7.html) |
| DE (1) | DE60233655D1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2331561T3 (cg-RX-API-DMAC7.html) |
| MY (1) | MY148432A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI345978B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002080935A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1384825A (zh) | 1999-08-31 | 2002-12-11 | 马克西亚药品公司 | 亚苄基-噻唑烷二酮及其类似物以及它们在治疗糖尿病中的应用 |
| BR0207846A (pt) | 2001-03-07 | 2005-09-13 | Incyte San Diego Inc | Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas |
| JP2004523571A (ja) | 2001-03-08 | 2004-08-05 | マキシア・ファーマシューティカルズ・インコーポレイテッド | Rxr活性化分子 |
| US20030045553A1 (en) * | 2001-04-04 | 2003-03-06 | Bussolari Jacqueline C. | Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators |
| EP1270012A1 (en) * | 2001-06-21 | 2003-01-02 | Pfizer Products Inc. | Use of pulmonary administration of insulin for treatment of diabetes |
| JP2005513026A (ja) * | 2001-11-15 | 2005-05-12 | インサイト サン ディエゴ インコーポレイテッド | 高コレステロール血症、異脂肪血症および他の代謝障害;癌、および他の疾患を治療するn−置換複素環 |
| US7196108B2 (en) * | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
| US7102000B2 (en) | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
| DE10258008B4 (de) * | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| DE10258007B4 (de) | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| KR20060105431A (ko) * | 2003-06-27 | 2006-10-11 | 닥터 레디스 리서치 파운데이션 | 발라글리타존 및 당뇨병치료제 화합물을 포함하는 조성물 |
| CN1319956C (zh) * | 2003-09-12 | 2007-06-06 | 深圳市海粤门生物科技开发有限公司 | 一种噻唑烷二酮的衍生物及其药用制剂的制备方法和应用 |
| CN1964706A (zh) | 2004-03-17 | 2007-05-16 | 拉斯·M·拉森 | 通过抑制视觉周期预防视网膜病 |
| DE102006028862A1 (de) | 2006-06-23 | 2007-12-27 | Merck Patent Gmbh | 3-Amino-imidazo[1,2-a]pyridinderivate |
| DE102007008420A1 (de) | 2007-02-21 | 2008-08-28 | Merck Patent Gmbh | Benzimidazolderivate |
| DE102007048716A1 (de) | 2007-10-11 | 2009-04-23 | Merck Patent Gmbh | Imidazo[1,2-a]pyrimidinderivate |
| CA2711673A1 (en) * | 2008-01-31 | 2009-08-06 | Astellas Pharma Inc. | Pharmaceutical compositions for treating fatty liver disease |
| DE102008017590A1 (de) | 2008-04-07 | 2009-10-08 | Merck Patent Gmbh | Glucopyranosidderivate |
| EP2291189B1 (en) | 2008-05-22 | 2014-10-01 | AstraZeneca AB | Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same |
| ES2380408T3 (es) | 2008-08-28 | 2012-05-11 | Pfizer Inc. | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol |
| WO2010141690A2 (en) * | 2009-06-04 | 2010-12-09 | Dara Biosciences, Inc. | Indane analogs and use as pharmaceutical agents and process of making |
| US8163704B2 (en) * | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| US8669380B2 (en) | 2009-11-02 | 2014-03-11 | Pfizer Inc. | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US9585857B2 (en) | 2013-01-18 | 2017-03-07 | Cornell University | Methods of treating diseases associated with high-fat diet and vitamin A deficiency using retinoic acid receptor agonists |
| EP2774619B1 (de) | 2013-03-04 | 2016-05-18 | BioActive Food GmbH | Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen |
| EP2944311A1 (de) | 2014-05-16 | 2015-11-18 | BioActive Food GmbH | Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen |
| JOP20210009A1 (ar) | 2018-07-19 | 2021-01-12 | Astrazeneca Ab | طرق لعلاج HFpEF باستعمال داباجليفلوزين وتركيبات تشمله |
| JP2023536009A (ja) | 2020-07-27 | 2023-08-23 | アストラゼネカ・アクチエボラーグ | ダパグリフロジンによる慢性腎疾患の処置方法 |
| WO2022208172A1 (en) | 2021-04-01 | 2022-10-06 | Astrazeneca Uk Limited | Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition |
| WO2023144722A1 (en) | 2022-01-26 | 2023-08-03 | Astrazeneca Ab | Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes |
| WO2024259383A2 (en) * | 2023-06-14 | 2024-12-19 | President And Fellows Of Harvard College | Ion channel binders and uses thereof |
| IL329013A (en) | 2023-12-15 | 2026-08-01 | Astrazeneca Ireland Ltd | SGLT2 inhibitors and baxadrostat for the treatment of chronic kidney disease and hypertension |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997010819A1 (en) * | 1995-09-18 | 1997-03-27 | Ligand Pharmaceuticals Incorporated | Treating niddm with rxr agonists |
| WO2001074835A1 (en) * | 2000-03-30 | 2001-10-11 | Bristol-Myers Squibb Company | O-glucosylated benzamide sglt2 inhibitors and method |
| WO2001074834A1 (en) * | 2000-03-30 | 2001-10-11 | Bristol-Myers Squibb Company | O-aryl glucoside sglt2 inhibitors and method |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US651003A (en) * | 1899-10-12 | 1900-06-05 | Solomon W Bates | Bicycle-pump. |
| JPH0253573A (ja) * | 1988-08-11 | 1990-02-22 | Nippon Riki Kk | ラチェットレンチの製造法 |
| US5731299A (en) * | 1992-05-29 | 1998-03-24 | The Procter & Gamble Company | Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
| US5731292A (en) * | 1992-11-12 | 1998-03-24 | Tanabe Seiyaku Co., Ltd. | Dihydrochalcone derivatives which are hypoglycemic agents |
| CA2102591C (en) * | 1992-11-12 | 2000-12-26 | Kenji Tsujihara | Hypoglycemic agent |
| JP2906978B2 (ja) * | 1993-02-25 | 1999-06-21 | 田辺製薬株式会社 | 血糖降下剤 |
| US6046222A (en) * | 1993-09-15 | 2000-04-04 | Warner-Lambert Company | Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
| JP2847695B2 (ja) * | 1994-05-11 | 1999-01-20 | 田辺製薬株式会社 | 血糖降下剤 |
| US5830873A (en) * | 1994-05-11 | 1998-11-03 | Tanabe Seiyaku Co., Ltd. | Propiophenone derivative and a process for preparing the same |
| JP3065235B2 (ja) | 1995-11-07 | 2000-07-17 | 田辺製薬株式会社 | プロピオフェノン誘導体およびその製法 |
| JP3059088B2 (ja) * | 1995-11-07 | 2000-07-04 | 田辺製薬株式会社 | プロピオフェノン誘導体およびその製法 |
| US5732199A (en) * | 1996-09-25 | 1998-03-24 | Behavior Tech Computer Corporation | Control method and device of scanner with built-in plug-and-play printer port |
| ATE216704T1 (de) * | 1996-12-26 | 2002-05-15 | Tanabe Seiyaku Co | Propiophenonderivate und verfahren zu ihrer herstellung |
| JP3055135B2 (ja) * | 1996-12-26 | 2000-06-26 | 田辺製薬株式会社 | プロピオフェノン誘導体及びその製法 |
| US6153632A (en) * | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
| WO1998057635A1 (en) | 1997-06-18 | 1998-12-23 | Smithkline Beecham Plc | Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor |
| JP2000080041A (ja) | 1998-03-09 | 2000-03-21 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| TWI249401B (en) | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| CN1384825A (zh) | 1999-08-31 | 2002-12-11 | 马克西亚药品公司 | 亚苄基-噻唑烷二酮及其类似物以及它们在治疗糖尿病中的应用 |
| EP1213296B1 (en) | 1999-08-31 | 2004-04-14 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| PE20010580A1 (es) | 1999-09-03 | 2001-05-25 | Takeda Chemical Industries Ltd | Composicion farmaceutica para tratar la diabetes |
| JP2001192375A (ja) * | 1999-10-29 | 2001-07-17 | Takeda Chem Ind Ltd | オキシイミノアルカン酸誘導体の結晶 |
| AR031078A1 (es) | 1999-10-29 | 2003-09-10 | Takeda Pharmaceutical | Compuesto acido (e)-4-[4-(5-metil-2-fenil-4-oxalilmetoxi)benziloxiimino]-4-fenilbutirico cristalino, composicion farmaceutica que lo comprende y su uso para fabricar esta ultima. |
| CA2390923A1 (en) * | 1999-11-10 | 2001-05-31 | Takeda Chemical Industries, Ltd. | 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| DE60121988T2 (de) * | 2000-10-30 | 2007-02-15 | Ortho-Mcneil Pharmaceutical, Inc. | Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln |
| SK287786B6 (sk) | 2000-12-28 | 2011-09-05 | Kissei Pharmaceutical Co., Ltd. | Glukopyranosyloxypyrazolový derivát, farmaceutická kompozícia alebo kombinácia s jeho obsahom a ich použitie |
| US20030045553A1 (en) * | 2001-04-04 | 2003-03-06 | Bussolari Jacqueline C. | Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators |
-
2002
- 2002-04-03 JP JP2002578974A patent/JP4590158B2/ja not_active Expired - Fee Related
- 2002-04-03 ES ES02715273T patent/ES2331561T3/es not_active Expired - Lifetime
- 2002-04-03 US US10/115,725 patent/US6838442B2/en not_active Expired - Lifetime
- 2002-04-03 CA CA2443325A patent/CA2443325C/en not_active Expired - Lifetime
- 2002-04-03 DE DE60233655T patent/DE60233655D1/de not_active Expired - Lifetime
- 2002-04-03 AT AT02715273T patent/ATE442148T1/de not_active IP Right Cessation
- 2002-04-03 CN CNB02810482XA patent/CN100384430C/zh not_active Expired - Lifetime
- 2002-04-03 EP EP02715273A patent/EP1392326B1/en not_active Expired - Lifetime
- 2002-04-03 WO PCT/US2002/010542 patent/WO2002080935A1/en not_active Ceased
- 2002-04-04 TW TW091106917A patent/TWI345978B/zh not_active IP Right Cessation
- 2002-04-04 MY MYPI20021222A patent/MY148432A/en unknown
-
2003
- 2003-02-24 US US10/372,517 patent/US20030195235A1/en not_active Abandoned
-
2007
- 2007-10-24 US US11/923,187 patent/US8183213B2/en not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997010819A1 (en) * | 1995-09-18 | 1997-03-27 | Ligand Pharmaceuticals Incorporated | Treating niddm with rxr agonists |
| WO2001074835A1 (en) * | 2000-03-30 | 2001-10-11 | Bristol-Myers Squibb Company | O-glucosylated benzamide sglt2 inhibitors and method |
| WO2001074834A1 (en) * | 2000-03-30 | 2001-10-11 | Bristol-Myers Squibb Company | O-aryl glucoside sglt2 inhibitors and method |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4590158B2 (ja) | 2010-12-01 |
| US6838442B2 (en) | 2005-01-04 |
| EP1392326A1 (en) | 2004-03-03 |
| CN1511038A (zh) | 2004-07-07 |
| US20030055091A1 (en) | 2003-03-20 |
| CA2443325C (en) | 2011-06-14 |
| CA2443325A1 (en) | 2002-10-17 |
| TWI345978B (en) | 2011-08-01 |
| ATE442148T1 (de) | 2009-09-15 |
| EP1392326B1 (en) | 2009-09-09 |
| DE60233655D1 (de) | 2009-10-22 |
| JP2004529914A (ja) | 2004-09-30 |
| US20030195235A1 (en) | 2003-10-16 |
| WO2002080935A1 (en) | 2002-10-17 |
| US8183213B2 (en) | 2012-05-22 |
| ES2331561T3 (es) | 2010-01-08 |
| MY148432A (en) | 2013-04-30 |
| US20090075864A1 (en) | 2009-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100577175C (zh) | 包括葡萄糖重吸收抑制剂和ppar调节剂的联合疗法 | |
| JP4590158B2 (ja) | グルコース再吸収阻害剤およびレチノイド−x受容体モジュレーターを含んで成る併用療法 | |
| DE69826811T4 (de) | Zusammensetzungen für die Verwendung bei der Behandlung und Prävention von Hyperurikämie | |
| KR20090103879A (ko) | 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법 | |
| RU2358738C2 (ru) | Лекарственные средства для лечения сахарного диабета | |
| KR101567660B1 (ko) | 진성 당뇨병을 치료하기 위한 병용제 | |
| CN102209532A (zh) | 减少小而致密的ldl颗粒的方法 | |
| US5708012A (en) | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus | |
| US20090227493A1 (en) | Combined drug for treating diabetes | |
| TW201521727A (zh) | 使用巴比妥酸鹽衍生物來降低尿酸位準的方法 | |
| US20180333399A1 (en) | Method of improving liver function | |
| US20090012067A1 (en) | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | |
| JP2000500490A (ja) | 糖尿病治療用の4−ヒドロキシクマリン−3−カルボキシアミド | |
| HK1131742A (en) | Combination therapy comprising glucose reabsorption inhibitors and ppar modulators | |
| CN1976696B (zh) | 用于预防或治疗脂质代谢异常的医药组合物 | |
| CN101115483A (zh) | 含有FBPase抑制剂的药物组合物 | |
| US10759749B2 (en) | Therapeutic agent for diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20080430 |